Hot pre-market trades in US stocks: AMD up 3.12% in pre-market, Raymond James upgrades rating, driven by dual engines of AI demand and market share increase

Popular Pre-Market Trades in U.S. Stocks

AMD is up 3.12% in pre-market trading. Based on recent key news:

1. On August 25, Raymond James upgraded AMD's rating from "Outperform" to "Strong Buy," raising the target price from $565 to $641. This rating upgrade reflects optimistic expectations for the growth of AMD's server CPU demand, driving the stock price up.

2. On August 22, data from Mercury Research showed that AMD captured over 30% of the x86 client CPU shipment share for the first time in Q2 2026. This increase in market share demonstrates AMD's competitiveness in the desktop and mobile processor markets, further boosting investor confidence.

3. On August 25, analysts are generally optimistic about AMD's AI server CPU market prospects, expecting the market to grow at a compound annual growth rate of 44% over the next five years. This optimistic market outlook supports AMD's stock price. AI demand is driving growth in the chip industry, and the market is optimistic.

Top Gainers in U.S. Pre-Market Trading

iRobot is up 240.91% in pre-market trading. There are no significant recent news; trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no_news

Polestar Automotive UK PLC - CW 27 is up 142.53% in pre-market trading, with no significant recent news. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

CID Holdco is up 93.53% in pre-market trading. Based on recent key news:

1. On August 25, Expion's stock price rose about 80% due to its major strategic expansion in the upstream energy sector. This move is seen as a positive development for the company's business, significantly boosting the stock price. Source: Benzinga

2. On August 25, Valion Bio Inc announced that the Ukrainian Ministry of Health accepted its regulatory documents for Entolimod for formal review, with the stock price dropping 14.8% in pre-market trading after rising over 35% on Monday. This news is significant for the company's future development. Source: Benzinga

3. On August 25, Aclaris Therapeutics Inc's stock price fell 12.7% in pre-market trading after releasing optimistic quarterly results. Despite good performance, the market's reaction was poor, leading to a decline in stock price. Source: Benzinga The expansion in the energy sector has drawn attention